Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

By B. Escudier, C. Porta, M. Schmidinger, N. Rioux-Leclercq, A. Bex, Vincent S. Khoo, V. Gruenvald, A. Horwich. Annals of Oncology, 2010

1,204 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/7d03757449d10442a2c45f4c9bb3961b60d5fc8f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. F. Bray
2. A. Jemal

In Molecular Biology

1. B. Rini

In Pulmonary and Respiratory Medicine

1. B. Rini
2. A. Jemal

Citations in the corpus

• Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma (2015, neutral): “Peripheral edema 17 (4) 0 56 (14) 2 (1)”
• Pazopanib versus sunitinib in metastatic renal-cell carcinoma. (2013, neutral): “Mucosal inflammation‡ 61 (11) 3 (1) 0 141 (26) 16 (3) 0”
• Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial (2014, background): “An understanding of the mechanisms involved in the pathogenesis of renal cell carcinoma (RCC) led to development of treatment options that inhibit vascular endothelial growth factor (VEGF)– mediated signaling or the mammalian target of rapamycin pathway.(1,2) Although these treatment options have de”
• International variations and trends in renal cell carcinoma incidence and mortality. (2015, methodology): “In the USA, the declines were more pronounced for blacks, starting from the 1990s (Figs.”